Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids. J of Skin 2024, 8 (2), s397. https://doi.org/10.25251/skin.8.supp.397.